Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Get Free Report) was the target of a large growth in short interest in October. As of October 30th, there was short interest totaling 4,836 shares, a growth of 62.8% from the October 15th total of 2,971 shares. Based on an average daily volume of 18,086 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.2% of the shares of the stock are sold short.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cardio Diagnostics in a research report on Tuesday, September 8th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company has a consensus rating of “Sell”.
Check Out Our Latest Stock Analysis on CDIO
Hedge Funds Weigh In On Cardio Diagnostics
An institutional investor recently bought a new position in Cardio Diagnostics stock. Renaissance Technologies LLC purchased a new stake in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 15,348 shares of the company’s stock, valued at approximately $30,000. Renaissance Technologies LLC owned about 0.52% of Cardio Diagnostics as of its most recent SEC filing. Hedge funds and other institutional investors own 8.06% of the company’s stock.
Cardio Diagnostics Stock Up 5.1%
Shares of CDIO traded up $0.10 during mid-day trading on Monday, hitting $1.97. 505 shares of the company’s stock traded hands, compared to its average volume of 1,171,424. Cardio Diagnostics has a 1 year low of $0.97 and a 1 year high of $7.91. The firm has a market capitalization of $5.82 million, a P/E ratio of -0.78 and a beta of 2.32. The business’s 50-day moving average price is $1.85 and its 200-day moving average price is $2.06.
Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) last posted its earnings results on Friday, November 6th. The company reported ($0.59) earnings per share for the quarter. Cardio Diagnostics had a negative return on equity of 89.41% and a negative net margin of 40,543.75%.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops blood-based tests and technology for cardiovascular disease assessment. Its platform combines genetic and epigenetic information with artificial intelligence to support more personalized evaluation of heart disease. The company’s offerings include Epi+Gen CHD, designed to assess a person’s risk of coronary heart disease, and PrecisionCHD, a test intended to help identify coronary heart disease in people being evaluated for the condition. The tests are designed to complement clinical assessment and are not a substitute for care from a health professional.
Featured Articles
- Five stocks we like better than Cardio Diagnostics
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
